Amphastar Pharmaceuticals (AMPH) Accumulated Expenses (2013 - 2026)

Amphastar Pharmaceuticals' Accumulated Expenses history runs 14 years deep, the most recent figure standing at $117.2 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 4.82% year-over-year to $117.2 million; the TTM figure through Mar 2026 stood at $117.2 million (down 4.82% YoY), while the FY2025 annual figure was $115.8 million, down 8.52% from the prior year.
• Accumulated Expenses was $117.2 million for Q1 2026 at Amphastar Pharmaceuticals, up from $115.8 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $198.7 million in Q2 2023 to a low of $63.7 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $109.3 million across 5 years, with a median of $115.8 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 198.38% in 2023, then plunged 49.96% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $63.7 million in 2022, then rose by 6.57% to $67.9 million in 2023, then soared by 86.29% to $126.5 million in 2024, then fell by 8.52% to $115.8 million in 2025, then increased by 1.24% to $117.2 million in 2026.
• The last three Accumulated Expenses figures came in at $117.2 million (Q1 2026), $115.8 million (Q4 2025), and $150.3 million (Q3 2025), per Business Quant data.